IPXL SEC 보고서 - Impax Laboratories, Inc.- 연례 보고, 기업 사업 설명서, 유가증권계출서

기본 통계

CIK

1003642

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Impax Laboratories, Inc.

SEC Filings (Chronological Order)

이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.

August 12, 2025	REVOKED	REVOKED UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION SECURITIES EXCHANGE ACT OF 1934 Release No.
February 14, 2019	SC 13G/A	IPXL / Impax Laboratories, Inc. / MAVERICK CAPITAL LTD - AMENDMENT NO 1 Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No 1) IMPAX LABORATORIES, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 45256B101 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 14, 2019	EX-24.A	Power of Attorney Exhibit 24.A Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that I, Lee S. Ainslie III, hereby make, constitute and appoint Mark Gurevich as my agent and attorney-in-fact for the purpose of executing (i) in my personal capacity or (ii) in my capacity as manager or other officer or representative of Maverick Capital Management, LLC, Maverick Capital, Ltd. or any affiliate of either, all document
February 14, 2019	EX-99.A	Joint Filing Agreement Exhibit 99.A Joint Filing Agreement The undersigned hereby agree that the statement on Schedule 13G/A with respect to the Common Stock, $0.01 par value of Impax Laboratories, Inc., dated as of February 14, 2019, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provi
February 14, 2019	EX-24.B	Power of Attorney Exhibit 24.B Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that I, Andrew H. Warford, hereby make, constitute and appoint Mark Gurevich as my agent and attorney-in-fact for the purpose of executing (i) in my personal capacity or (ii) in my capacity as manager or other officer or representative of Maverick Capital, Ltd. or any affiliate of either, all documents to be filed with or delivered to
February 12, 2019	SC 13G/A	IPXL / Impax Laboratories, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Impax Laboratories, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45256B101 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
June 7, 2018	EX-99.(A)(1)(D)	Impax Laboratories, LLC Announces Results Of Tender Offer for 2.00% Convertible Senior Notes Due 2022 EX-99.(a)(1)(D) Exhibit (a)(1)(D) Impax Laboratories, LLC Announces Results Of Tender Offer for 2.00% Convertible Senior Notes Due 2022 HAYWARD, Cal., June 5, 2018 /PRNewswire/ — Impax Laboratories, LLC (“Impax” or the “Company”), a wholly-owned subsidiary of Amneal Pharmaceuticals, Inc. (NYSE: AMRX), announced today the final results of its previously announced cash tender offer (the “Offer”) to
June 7, 2018	SC TO-I/A	IPXL / Impax Laboratories, Inc. AMENDMENT NO. 1 TO SCHEDULE TO Amendment No. 1 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) IMPAX LABORATORIES, LLC (Name of Subject Company (Issuer)) IMPAX LABORATORIES, LLC (Name of Filing Person (Issuer)) 2.00% CONVERTIBLE SENIOR NOTES DUE 2022 (Title of Cl
May 10, 2018	10-Q	IPXL / Impax Laboratories, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34263 Impax Labo
May 7, 2018	EX-99.(A)(1)(C)	Notice of Offer to Repurchase for Cash and Right to Convert All 2.00% Convertible Senior Notes due 2022 Impax Laboratories, LLC 100% of the principal amount of Notes pursuant to the Company Repurchase Notice, Notice of Entry into Supplemental Indentu EX-99.(a)(1)(C) Exhibit (a)(1)(C) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Notes (as defined below). The tender offer is made solely by the Company Repurchase Notice, Notice of Entry into Supplemental Indenture and Offer to Repurchase, dated May 7, 2018, and any amendments or supplements thereto. The offer is not being made to, nor will tenders be ac
May 7, 2018	EX-99.(A)(1)(A)	COMPANY REPURCHASE NOTICE, NOTICE OF ENTRY INTO SUPPLEMENTAL INDENTURE AND OFFER TO REPURCHASE TO HOLDERS OF 2.00% CONVERTIBLE SENIOR NOTES DUE 2022 ISSUED BY IMPAX LABORATORIES, LLC CUSIP NUMBER: 45256BAE1 EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) COMPANY REPURCHASE NOTICE, NOTICE OF ENTRY INTO SUPPLEMENTAL INDENTURE AND OFFER TO REPURCHASE TO HOLDERS OF 2.00% CONVERTIBLE SENIOR NOTES DUE 2022 ISSUED BY IMPAX LABORATORIES, LLC CUSIP NUMBER: 45256BAE1 NOTICE IS HEREBY GIVEN pursuant to the terms and conditions of Section 4.10 of the Indenture, dated as of June 30, 2015 (the “Base Indenture”
May 7, 2018	EX-99.(A)(1)(B)	REPURCHASE NOTICE TO: IMPAX LABORATORIES, LLC Global Bondholder Services, as Depository Agent EX-99.(a)(1)(B) Exhibit (a)(1)(B) REPURCHASE NOTICE TO: IMPAX LABORATORIES, LLC Global Bondholder Services, as Depository Agent The undersigned registered owner of Notes hereby irrevocably acknowledges receipt of a notice from Impax Laboratories, LLC (the “Company”) regarding the right of Holders to elect to require the Company to repurchase the Notes and requests and instructs the Company to repa
May 7, 2018	SC TO-I	IPXL / Impax Laboratories, Inc. SCHEDULE TO Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 IMPAX LABORATORIES, LLC (Name of Subject Company (Issuer)) IMPAX LABORATORIES, LLC (Name of Filing Person (Issuer)) 2.00% Convertible Senior Notes Due 2022 (Title of Class of Securities) 45256BAE1 (CUSIP Num
May 7, 2018	EX-10.2	Revolving Credit Agreement, dated as of May 4, 2018, by and among Amneal Pharmaceuticals LLC, as the borrower, the other loan parties from time to time party thereto, JPMorgan Chase Bank, N.A., as administrative agent and collateral agent and the lenders and other parties party thereto. EX-10.2 Exhibit 10.2 EXECUTION VERSION $500,000,000 REVOLVING CREDIT AGREEMENT, dated as of May 4, 2018, among AMNEAL PHARMACEUTICALS LLC, as the Borrower, THE LENDERS PARTY HERETO, JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent, JPMORGAN CHASE BANK, N.A., BANK OF AMERICA, N.A. and RBC CAPITAL MARKETS, as Bookrunners and Arrangers, BANK OF AMERICA, N.A. and ROYAL BANK OF C
May 7, 2018	EX-10.5	Termination Agreement, dated as of May 7, 2018 , between Impax Laboratories, LLC (f/k/a Impax Laboratories, Inc.) and Royal Bank of Canada. EX-10.5 Exhibit 10.5 TERMINATION AGREEMENT dated as of May 7, 2018 Between IMPAX LABORATORIES, LLC (f/k/a IMPAX LABORATORIES, INC.) and ROYAL BANK OF CANADA THIS TERMINATION AGREEMENT (this “Agreement”) with respect to the Call Spread Confirmations (as defined below) is made as of May 7, 2018, between Impax Laboratories, LLC (formerly known as Impax Laboratories, Inc.) (“Company”) and Royal Bank o
May 7, 2018	EX-10.4	Revolving Loan Guarantee and Collateral Agreement, dated as of May 4, 2018, by and among the loan parties from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent. EX-10.4 Exhibit 10.4 Execution Version ABL GUARANTEE AND COLLATERAL AGREEMENT, dated as of May 4, 2018, among AMNEAL PHARMACEUTICALS LLC, as the Borrower, each other Grantor party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent Reference is made to the ABL/Term Loan Intercreditor Agreement dated as of May 4, 2018 (as amended, restated, supplemented or otherwise
May 7, 2018	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2018 IMPAX LABORATORIES, LLC (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of Incorporation) (Commission File Number) (IRS Emp
May 7, 2018	EX-10.3	Term Loan Guarantee and Collateral Agreement, dated as of May 4, 2018, by and among the loan parties from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent. EX-10.3 Exhibit 10.3 Execution Version TERM LOAN GUARANTEE AND COLLATERAL AGREEMENT, dated as of May 4, 2018, among AMNEAL PHARMACEUTICALS LLC, as the Borrower, each other Grantor party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent Reference is made to the ABL/Term Loan Intercreditor Agreement dated as of May 4, 2018 (as amended, restated, supplemented or othe
May 7, 2018	EX-10.1	Term Loan Credit Agreement, dated as of May 4, 2018, by and among Amneal Pharmaceuticals LLC, as the borrower, JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders and other parties party thereto. EX-10.1 Exhibit 10.1 EXECUTION VERSION $2,700,000,000 TERM LOAN CREDIT AGREEMENT, dated as of May 4, 2018, among AMNEAL PHARMACEUTICALS LLC, as the Borrower, THE LENDERS PARTY HERETO, JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent, and JPMORGAN CHASE BANK, N.A., BANK OF AMERICA, N.A. and RBC CAPITAL MARKETS, as Bookrunners and Arrangers TABLE OF CONTENTS Page ARTICLE I Def
May 7, 2018	EX-3.3	Limited Liability Company Agreement of Impax Laboratories, LLC. EX-3.3 Exhibit 3.3 LIMITED LIABILITY COMPANY AGREEMENT OF IMPAX LABORATORIES, LLC This LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”) of Impax Laboratories, LLC (the “Company”), effective as of the Conversion Effective Time (as defined below), is entered into by Atlas Holdings, Inc., as the sole member of the Company. WHEREAS, on the date hereof, Impax Laboratories, Inc., a Delaware corpor
May 7, 2018	EX-4.1	Second Supplemental Indenture. EX-4.1 Exhibit 4.1 SECOND SUPPLEMENTAL INDENTURE SECOND SUPPLEMENTAL INDENTURE, dated as of May 4, 2018 (this “Second Supplemental Indenture”), to the Indenture dated as of June 30, 2015 (the “Indenture”), as amended by that certain First Supplemental Indenture dated as of November 6, 2017, each between Impax Laboratories, Inc. (the “Company”), a Delaware corporation, and Wilmington Trust, Nationa
May 7, 2018	EX-3.2	Form of Amended and Restated Bylaws of Impax Laboratories, Inc. EX-3.2 Exhibit 3.2 BYLAWS OF IMPAX LABORATORIES, INC. (a Delaware corporation) Adopted as of [•], 20[•] TABLE OF CONTENTS Page ARTICLE I. IDENTIFICATION; OFFICES 1 SECTION 1. NAME 1 SECTION 2. PRINCIPAL AND BUSINESS OFFICES 1 SECTION 3. REGISTERED AGENT AND OFFICE 1 SECTION 4. PLACE OF KEEPING CORPORATE RECORDS 1 ARTICLE II. STOCKHOLDERS 1 SECTION 1. ANNUAL MEETING 1 SECTION 2. SPECIAL MEETING 1 S
May 7, 2018	EX-3.1	Form of Amended and Restated Certificate of Incorporation of Impax Laboratories, Inc. EX-3.1 Exhibit 3.1 IMPAX LABORATORIES, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Impax Laboratories, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies as follows: FIRST: The name of this corporation is Impax Laboratories, Inc. and the original Certificate of Incorporation was filed with the Secretar
April 30, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2018 IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of Incorporation) (Commission File Number) (IRS
April 30, 2018	EX-99.1	AMNEAL AND IMPAX RECEIVE FTC CLEARANCE FOR BUSINESS COMBINATION EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE CONTACTS: Amneal Apurva Saraf (631) 742-7674 Impax Mark Donohue (215) 558-4526 AMNEAL AND IMPAX RECEIVE FTC CLEARANCE FOR BUSINESS COMBINATION BRIDGEWATER, NJ, April 27, 2018 – Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Federal Trade Commission (FTC) has cleared the Amneal and Impax business combin
April 13, 2018	10-K/A	IPXL / Impax Laboratories, Inc. 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-
April 10, 2018	SC 13G/A	IPXL / Impax Laboratories, Inc. / VANGUARD GROUP INC Passive Investment impaxlaboratoriesinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6 )* Name of issuer: Impax Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 45256B101 Date of Event Which Requires Filing of this Statement: March 29, 2018 Check the appropriate
April 5, 2018	CT ORDER	IPXL / Impax Laboratories, Inc. CT ORDER begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;F5AF4@-C(O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F#R A(,4X $XWT@P1(")-C+@<2G.PQ,C P'0+(,C.C$?\;)?P "# #6)0?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T, T)25%3T8-"B @(" @ M(" @#0HV,2 P(&]B:@T\/"]#(#8Y+T9I;'1E7!E+T]B M:E-T;3X^<@!&WIH$VE-@TA9"# M:@M;8$M!4FCS[[LSTJ[6BNVTOI0>QMJ=UWXS.M9:<(,H1;HBP1RFU2PJ50 M1#/"M>+D@=Y,IY.L
March 27, 2018	EX-99.1	Impax Shareholders Approve Proposed Business Combination with Amneal FOR IMMEDIATE RELEASE CONTACTS: Amneal Apurva Saraf (631) 742-7674 Impax Mark Donohue (215) 558-4526 Impax Shareholders Approve Proposed Business Combination with Amneal BRIDGEWATER, NJ, March 27, 2018 – Impax Laboratories, Inc.
March 27, 2018	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2018 IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of (Commission File Number) (IRS Employer Incorpora
March 19, 2018	EX-99.1	IMPAX LABORATORIES, INC. 2.00% CONVERTIBLE SENIOR NOTES DUE 2022 CUSIP 45256BAE1 NOTICE OF MERGER EVENT March 19, 2018 Exhibit 99.1 IMPAX LABORATORIES, INC. 2.00% CONVERTIBLE SENIOR NOTES DUE 2022 CUSIP 45256BAE1 NOTICE OF MERGER EVENT March 19, 2018 We refer to that certain Indenture (the “Original Indenture”), dated as of June 30, 2015, relating to the 2.00% Convertible Senior Notes due 2022 (the “Notes”) of Impax Laboratories, Inc., a Delaware corporation (“Impax” or the “Company”), between the Company and Wilm
March 19, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2018 IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of (Commission File Number) (IRS Employer Incorpora
March 19, 2018	EX-99.1	IMPAX LABORATORIES, INC. 2.00% CONVERTIBLE SENIOR NOTES DUE 2022 CUSIP 45256BAE1 NOTICE OF MERGER EVENT March 19, 2018 Exhibit 99.1 IMPAX LABORATORIES, INC. 2.00% CONVERTIBLE SENIOR NOTES DUE 2022 CUSIP 45256BAE1 NOTICE OF MERGER EVENT March 19, 2018 We refer to that certain Indenture (the “Original Indenture”), dated as of June 30, 2015, relating to the 2.00% Convertible Senior Notes due 2022 (the “Notes”) of Impax Laboratories, Inc., a Delaware corporation (“Impax” or the “Company”), between the Company and Wilm
March 19, 2018	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2018 IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of (Commission File Number) (IRS Employer Incorpora
March 19, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2018 IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of (Commission File Number) (IRS Employer Incorpora
March 19, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2018 IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of (Commission File Number) (IRS Employer Incorpora
March 15, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (“Impax”) and Amneal Pharmaceuticals LLC (“Amneal”) pursuant to the Business
March 7, 2018	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2018 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (Commission
March 2, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2018 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (Commission
March 2, 2018	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2018 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (Commission
March 2, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (“Impax”) and Amneal Pharmaceuticals LLC (“Amneal”) pursuant to the Business
March 1, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (“Impax”) and Amneal Pharmaceuticals LLC (“Amneal”) pursuant to the Business
March 1, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2018 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (Co
March 1, 2018	EX-99.1	Impax Reports Fourth Quarter and Full Year 2017 Results ‒ Q4 2017 Total Revenues of $183 Million; GAAP Net Loss Per Share of $4.18; Non-GAAP Adjusted Income Per Share of $0.11 ‒ ‒ Full Year 2017 Total Revenues of $776 Million; GAAP Net Loss Per Share Exhibit Impax Reports Fourth Quarter and Full Year 2017 Results ? Q4 2017 Total Revenues of $183 Million; GAAP Net Loss Per Share of $4.
March 1, 2018	EX-99.2	1 Fourth Quarter and Full Year 2017 Results March 1, 2018 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this exhibit992 1 Fourth Quarter and Full Year 2017 Results March 1, 2018 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management.
March 1, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2018 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (Co
March 1, 2018	EX-99.2	1 Fourth Quarter and Full Year 2017 Results March 1, 2018 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this exhibit992 1 Fourth Quarter and Full Year 2017 Results March 1, 2018 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management.
March 1, 2018	EX-99.1	Impax Reports Fourth Quarter and Full Year 2017 Results ‒ Q4 2017 Total Revenues of $183 Million; GAAP Net Loss Per Share of $4.18; Non-GAAP Adjusted Income Per Share of $0.11 ‒ ‒ Full Year 2017 Total Revenues of $776 Million; GAAP Net Loss Per Share Exhibit Impax Reports Fourth Quarter and Full Year 2017 Results ? Q4 2017 Total Revenues of $183 Million; GAAP Net Loss Per Share of $4.
March 1, 2018	EX-3.2.1	BYLAWS OF IMPAX LABORATORIES, INC. (a Delaware corporation) (Amended and Restated as of May 14, 2014) ARTICLE I EX-3.2.1 2 ipxl-12x31x2017x10kxexx321a.htm EXHIBIT 3.2.1 Exhibit 3.2.1 BYLAWS OF IMPAX LABORATORIES, INC. (a Delaware corporation) (Amended and Restated as of May 14, 2014) ARTICLE I OFFICES SECTION 1. OFFICES. The Corporation shall maintain its registered office in the State of Delaware at 32 Loockerman Square, Suite L-100, in the County of Kent, and its resident agent at such address is the Pren
March 1, 2018	EX-10.7	STOCK AND ASSET PURCHASE AGREEMENT by and among IMPAX LABORATORIES, INC. BORA PHARMACEUTICALS CO., LTD. Dated as of December 19, 2017 EX-10.7 12 ipxl-12x31x2017x10kxexx107.htm EXHIBIT 10.7 EXECUTION VERSION Exhibit 10.7 STOCK AND ASSET PURCHASE AGREEMENT by and among IMPAX LABORATORIES, INC. and BORA PHARMACEUTICALS CO., LTD. Dated as of December 19, 2017 SC1:4515121.14 TABLE OF CONTENTS Page ARTICLE I DEFINED TERMS 1.1 Interpretation; Construction 1 1.2 Certain Definitions 2 1.3 Other Definitional Provisions 11 ARTICLE II PURCH
March 1, 2018	EX-10.8	MASTER SUPPLY AGREEMENT IMPAX LABORATORIES, INC. BORA PHARMACEUTICALS CO., LTD IMPAX LABORATORIES (TAIWAN), INC. Manufacturing and Packaging of Pharmaceutical Products December 19, 2017 EXECUTION VERSION Exhibit 10.8 MASTER SUPPLY AGREEMENT Between IMPAX LABORATORIES, INC. And BORA PHARMACEUTICALS CO., LTD And IMPAX LABORATORIES (TAIWAN), INC. For Manufacturing and Packaging of Pharmaceutical Products December 19, 2017 SC1:4529841.10 AGREEMENT This Master Supply Agreement (the “Agreement”) by and between Impax Laboratories, Inc. (“Customer”), a corporation existing under the laws
March 1, 2018	EX-3.2.9	AMENDMENT NO. 8 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-3.2.9 11 ipxl-12x31x2017x10kxexx329.htm EXHIBIT 3.2.9 Exhibit 3.2.9 AMENDMENT NO. 8 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The auth
March 1, 2018	EX-3.2.5	AMENDMENT NO. 4 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.5 AMENDMENT NO. 4 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
March 1, 2018	EX-3.2.3	AMENDMENT NO. 2 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-3.2.3 5 ipxl-12x31x2017x10kxexx323.htm EXHIBIT 3.2.3 Exhibit 3.2.3 AMENDMENT NO. 2 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The autho
March 1, 2018	EX-3.2.7	AMENDMENT NO. 6 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-3.2.7 9 ipxl-12x31x2017x10kxexx327.htm EXHIBIT 3.2.7 Exhibit 3.2.7 AMENDMENT NO. 6 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The autho
March 1, 2018	EX-3.2.8	AMENDMENT NO. 7 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.8 AMENDMENT NO. 7 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
March 1, 2018	10-K	IPXL / Impax Laboratories, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34263 Impax Laborato
March 1, 2018	EX-3.2.4	AMENDMENT NO. 3 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.4 AMENDMENT NO. 3 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
March 1, 2018	EX-21.1	IMPAX LABORATORIES, INC. Exhibit 21.1 IMPAX LABORATORIES, INC. Subsidiaries of the Registrant as of the date of this report: Name of Subsidiary Jurisdiction of Incorporation or Organization Ownership Amedra Pharmaceuticals LLC Delaware 100 % Impax Holdings LLC Delaware 100 % Impax International Holdings, Inc. Delaware 100 % Impax Laboratories Ireland Limited Ireland 100 % Impax Laboratories (Netherlands) C.V. Netherlands
March 1, 2018	EX-3.2.2	AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC. Exhibit 3.2.2 AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC. The Amended and Restated Bylaws of Impax Laboratories, Inc. (the “Bylaws”) are hereby amended as follows: 1. Section 5 of Article II shall be amended and restated in its entirety to read as follows: “SECTION 5. QUORUM. At all meetings of stockholders, except where otherwise provided by statute, by the Certific
March 1, 2018	EX-3.2.10	AMENDMENT NO. 9 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.10 AMENDMENT NO. 9 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
March 1, 2018	EX-3.2.6	AMENDMENT NO. 5 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.6 AMENDMENT NO. 5 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
February 14, 2018	SC 13G/A	IPXL / Impax Laboratories, Inc. / Hound Partners, LLC Passive Investment SC 13G/A 1 d782137213g-a.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3) Impax Laboratories, Inc. (Name of Issuer) Common Stock, $.01 Par Value (Title of Class of Securities) 45256B101 (CUSIP Number) D
February 12, 2018	DEFM14A	Form of Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan.** Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-
February 12, 2018	EX-99.A	Joint Filing Agreement Exhibit A Joint Filing Agreement The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock, $0.
February 12, 2018	SC 13G	IPXL / Impax Laboratories, Inc. / MAVERICK CAPITAL LTD - SCHEDULE 13G Passive Investment SC 13G 1 ss7910113g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No ) IMPAX LABORATORIES, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 45256B101 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des
February 9, 2018	SC 13G/A	IPXL / Impax Laboratories, Inc. / VANGUARD GROUP INC Passive Investment impaxlaboratoriesinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5 )* Name of issuer: Impax Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 45256B101 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropri
February 8, 2018	SC 13G	IPXL / Impax Laboratories, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Impax Laboratories, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45256B101 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 6, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Document Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the
February 6, 2018	SC 13G/A	IPXL / Impax Laboratories, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Impax Laboratories Inc (Name of Issuer) Common Stock (Title of Class of Securities) 45256B101 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 1, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Document Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the
January 25, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Document Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (“Impax”) and Amneal Pharmaceuticals LLC (“Amneal”) pursuant to the
January 24, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2018 (January 23, 2018) Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction
January 24, 2018	8-K	IPXL / Impax Laboratories, Inc. 8-K (Current Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2018 (January 23, 2018) Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction
January 19, 2018	SC 13G/A	IPXL / Impax Laboratories, Inc. / BlackRock Inc. - 3G/A (Passive Investment) SC 13G/A 1 us45256b1017011718.txt us45256b1017011718.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) IMPAX LABORATORIES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 45256B101 - (CUSIP Number) December 31, 2017 - (Date of Event Which Requires Filing of this Statement) Check the appropriate
January 9, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2018 (January 9, 2018) Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction o
January 9, 2018	EX-99.1	J.P. Morgan Global Healthcare Conference January 9, 2018 + "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This communication includes “forward-looking statements” within the meaning of Section 27A of the Securitie exhibit991 J.P. Morgan Global Healthcare Conference January 9, 2018 + "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This communication includes ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements are based on our beliefs and assumptions.
January 9, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 ipxl-01x09x2018x701.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2018 (January 9, 2018) Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (Stat
January 9, 2018	EX-99.1	J.P. Morgan Global Healthcare Conference January 9, 2018 + "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This communication includes “forward-looking statements” within the meaning of Section 27A of the Securitie EX-99.1 2 exhibit991.htm EXHIBIT 99.1 J.P. Morgan Global Healthcare Conference January 9, 2018 + "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This communication includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements are based on o
January 9, 2018	8-K	IPXL / Impax Laboratories, Inc. 8-K (Current Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2018 (January 9, 2018) Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction o
January 9, 2018	EX-10.1	Separation Agreement dated as of January 8, 2018 between Michael J. Nestor and Impax Laboratories, Inc. Exhibit Separation Agreement This Separation Agreement (this ?Agreement? ) is entered into on January 8, 2018 by Michael J.
January 3, 2018	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Document Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the
December 29, 2017	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation)
December 29, 2017	8-K	IPXL / Impax Laboratories, Inc. 8-K (Current Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation)
December 22, 2017	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Document Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the
December 20, 2017	EX-10.2	Memorandum of Understanding dated as of December 16, 2017 by and among Amneal Pharmaceuticals LLC, Paul M. Bisaro, Impax Laboratories, Inc. and Atlas Holdings, Inc. EX-10.2 Exhibit 10.2 MEMORANDUM OF UNDERSTANDING THIS MEMORANDUM OF UNDERSTANDING (?MOU?), is made and entered into as of the 16th day of December, 2017 (the ?Effective Date?), by and among Amneal Pharmaceuticals LLC (the ?Company?), Paul M. Bisaro (?Bisaro?), Impax Laboratories, Inc. (?Impax?), Amneal Holdings, LLC (?Amneal Holdings?) (solely with respect to and in connection with its obligations
December 20, 2017	EX-2.1	Amendment No. 2 to the Business Combination Agreement, dated December 16, 2017. EX-2.1 Exhibit 2.1 AMENDMENT NO. 2 TO THE BUSINESS COMBINATION AGREEMENT This AMENDMENT NO. 2 (this ?Amendment?), dated as of December 16, 2017, to the Business Combination Agreement, dated as of October 17, 2017 (the ?BCA?), as amended by Amendment No. 1, dated as of November 21, 2017 (?Amendment No. 1?), by and among Impax Laboratories, Inc., a Delaware corporation (?Impax?), Atlas Holdings, Inc
December 20, 2017	8-K	IPXL / Impax Laboratories, Inc. 8-K (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2017 (December 16, 2017) IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of Incorporation) (Commi
December 20, 2017	EX-10.1	Employment Agreement dated as of December 16, 2017 by and among Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and Robert A. Stewart. EX-10.1 3 d491016dex101.htm EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of December 16, 2017, by and among Amneal Pharmaceuticals LLC (“Amneal”), Atlas Holdings, Inc. (“Holdings”) and Robert A. Stewart (the “Executive” and, collectively with Amneal and Holdings, the “Parties”). WITNESSETH: WHEREAS, Amneal has entered into that certain Busine
December 20, 2017	EX-10.1	Employment Agreement dated as of December 16, 2017 by and among Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and Robert A. Stewart. EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?) is entered into as of December 16, 2017, by and among Amneal Pharmaceuticals LLC (?Amneal?), Atlas Holdings, Inc. (?Holdings?) and Robert A. Stewart (the ?Executive? and, collectively with Amneal and Holdings, the ?Parties?). WITNESSETH: WHEREAS, Amneal has entered into that certain Business Combination Agreement (th
December 20, 2017	EX-10.2	Memorandum of Understanding dated as of December 16, 2017 by and among Amneal Pharmaceuticals LLC, Paul M. Bisaro, Impax Laboratories, Inc. and Atlas Holdings, Inc. EX-10.2 Exhibit 10.2 MEMORANDUM OF UNDERSTANDING THIS MEMORANDUM OF UNDERSTANDING (?MOU?), is made and entered into as of the 16th day of December, 2017 (the ?Effective Date?), by and among Amneal Pharmaceuticals LLC (the ?Company?), Paul M. Bisaro (?Bisaro?), Impax Laboratories, Inc. (?Impax?), Amneal Holdings, LLC (?Amneal Holdings?) (solely with respect to and in connection with its obligations
December 20, 2017	EX-2.1	Amendment No. 2 to the Business Combination Agreement, dated December 16, 2017. EX-2.1 Exhibit 2.1 AMENDMENT NO. 2 TO THE BUSINESS COMBINATION AGREEMENT This AMENDMENT NO. 2 (this ?Amendment?), dated as of December 16, 2017, to the Business Combination Agreement, dated as of October 17, 2017 (the ?BCA?), as amended by Amendment No. 1, dated as of November 21, 2017 (?Amendment No. 1?), by and among Impax Laboratories, Inc., a Delaware corporation (?Impax?), Atlas Holdings, Inc
December 20, 2017	425	IPXL / Impax Laboratories, Inc. 8-K (Prospectus) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2017 (December 16, 2017) IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of Incorporation) (Commi
December 19, 2017	8-K/A	IPXL / Impax Laboratories, Inc. 8-K/A (Current Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2017 (December 19, 2017) Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State
December 19, 2017	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d469800d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2017 (December 19, 2017) IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of
December 19, 2017	EX-99.1	Impax Announces Sale of Taiwan Manufacturing Facility EX-99.1 Exhibit 99.1 Impax Announces Sale of Taiwan Manufacturing Facility BRIDGEWATER, NJ, December 19, 2017 ? Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has entered into a definitive agreement to sell its manufacturing facility in Taiwan (?Impax Taiwan?), to Bora Pharmaceuticals Co, Ltd. (?Bora?). This sale supports Impax?s operational and cost improvement plans to streamlin
December 18, 2017	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Document Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the
December 5, 2017	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) 425 Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the Busin
November 23, 2017	8-K	IPXL / Impax Laboratories, Inc. 8-K (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 21, 2017 (November 21, 2017) IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of (Commission (IRS Empl
November 23, 2017	425	IPXL / Impax Laboratories, Inc. 8-K (Prospectus) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 21, 2017 (November 21, 2017) IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of (Commission (IRS Empl
November 21, 2017	EX-2.1	Amendment No. 1 to the Business Combination Agreement, dated November 21, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc., K2 Merger Sub Corporation, and Amneal Pharmaceuticals LLC. EX-2.1 Exhibit 2.1 AMENDMENT NO. 1 TO THE BUSINESS COMBINATION AGREEMENT This AMENDMENT NO. 1 (this ?Amendment?), dated as of November 21, 2017, to the Business Combination Agreement (the ?BCA?), dated as of October 17, 2017, by and among Impax Laboratories, Inc., a Delaware corporation (?Impax?), Atlas Holdings, Inc., a Delaware corporation and a wholly-owned Subsidiary of Impax (?Holdco?), K2 Me
November 21, 2017	8-K	IPXL / Impax Laboratories, Inc. 8-K (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 21, 2017 (November 21, 2017) IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of (Commission File Numb
November 21, 2017	425	IPXL / Impax Laboratories, Inc. 8-K (Prospectus) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 21, 2017 (November 21, 2017) IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of (Commission File Numb
November 21, 2017	EX-2.1	Amendment No. 1 to the Business Combination Agreement, dated November 21, 2017, by and among Impax Laboratories, Inc., Atlas Holdings, Inc., K2 Merger Sub Corporation, and Amneal Pharmaceuticals LLC. EX-2.1 Exhibit 2.1 AMENDMENT NO. 1 TO THE BUSINESS COMBINATION AGREEMENT This AMENDMENT NO. 1 (this ?Amendment?), dated as of November 21, 2017, to the Business Combination Agreement (the ?BCA?), dated as of October 17, 2017, by and among Impax Laboratories, Inc., a Delaware corporation (?Impax?), Atlas Holdings, Inc., a Delaware corporation and a wholly-owned Subsidiary of Impax (?Holdco?), K2 Me
November 14, 2017	EX-3.1	Amendment No. 9 to the Amended and Restated Bylaws of Impax Laboratories, Inc., as amended effective November 10, 2017. Exhibit AMENDMENT NO. 9 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the ?Bylaws?) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: ?SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor more t
November 14, 2017	8-K	IPXL / Impax Laboratories, Inc. 8-K (Current Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation)
November 9, 2017	425	IPXL / Impax Laboratories, Inc. 425 (Prospectus) Document Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the
November 9, 2017	EX-99.2	1 Third Quarter 2017 Results and Business Update November 9, 2017 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made EX-99.2 3 ex9928k.htm EXHIBIT 99.2 1 Third Quarter 2017 Results and Business Update November 9, 2017 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and
November 9, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation)
November 9, 2017	EX-99.1	Impax Reports Third Quarter 2017 Results ‒ Total Revenues of $206 Million; GAAP Loss Per Share of $0.69; Non-GAAP Adjusted Income Per Share of $0.23 ‒ ‒ Significant Progress on Operational and Cost Improvement Plans ‒ ‒ Company Announces Positive Res Document Impax Reports Third Quarter 2017 Results ? Total Revenues of $206 Million; GAAP Loss Per Share of $0.
November 9, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34263 Impax
November 7, 2017	EX-99.1	Impax Announces Successful Completion of Consent Solicitation with Respect to its 2.00% Convertible Senior Notes due 2022 EX-99.1 Exhibit 99.1 Impax Announces Successful Completion of Consent Solicitation with Respect to its 2.00% Convertible Senior Notes due 2022 HAYWARD, Calif., November 6, 2017 ? Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company (?Impax? or the ?Company?), announced today that it has received the consents necessary to amend and insert certain provisions (such amendments a
November 7, 2017	EX-4.1	Supplemental Indenture, dated November 6, 2017, by and between Impax Laboratories, Inc. and Wilmington Trust, National Association. Exhibit 4.1 EXECUTION VERSION FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE, dated as of November 6, 2017 (this First Supplemental Indenture), to the Indenture dated as of June 30, 2015 (the Indenture) between Impax Laboratories, Inc. (the Company), a Delaware corporation, and Wilmington Trust, National Association, a national banking association, as Trustee (the Trustee). Each
November 7, 2017	8-K	IPXL / Impax Laboratories, Inc. 8-K (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of Incorporation) (Commission File Number) (I
November 7, 2017	EX-4.1	Supplemental Indenture, dated November 6, 2017, by and between Impax Laboratories, Inc. and Wilmington Trust, National Association. EX-4.1 Exhibit 4.1 EXECUTION VERSION FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE, dated as of November 6, 2017 (this ?First Supplemental Indenture?), to the Indenture dated as of June 30, 2015 (the ?Indenture?) between Impax Laboratories, Inc. (the ?Company?), a Delaware corporation, and Wilmington Trust, National Association, a national banking association, as Trustee (the ?Trustee?
November 7, 2017	EX-99.1	Impax Announces Successful Completion of Consent Solicitation with Respect to its 2.00% Convertible Senior Notes due 2022 EX-99.1 Exhibit 99.1 Impax Announces Successful Completion of Consent Solicitation with Respect to its 2.00% Convertible Senior Notes due 2022 HAYWARD, Calif., November 6, 2017 ? Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company (?Impax? or the ?Company?), announced today that it has received the consents necessary to amend and insert certain provisions (such amendments a
November 7, 2017	425	IPXL / Impax Laboratories, Inc. 8-K (Prospectus) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of Incorporation) (Commission File Number) (I
October 30, 2017	425	Impax Laboratories 425 (Prospectus) Document Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the
October 25, 2017	425	Impax Laboratories 425 (Prospectus) 425 1 amnealimpax102517final.htm 425 Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (“Impax”) and Amneal Pharmaceuticals LLC
October 24, 2017	425	Impax Laboratories 425 (Prospectus) Document Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the
October 19, 2017	425	Impax Laboratories 425 (Prospectus) Document Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the
October 18, 2017	425	Impax Laboratories 425 (Prospectus) 425 Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the Busin
October 18, 2017	425	Filed by Amneal Pharmaceuticals LLC 425 Filed by Amneal Pharmaceuticals LLC pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Impax Laboratories, Inc.
October 17, 2017	425	Impax Laboratories 425 (Prospectus) 425 A STRATEGIC COMBINATION FOR LONG-TERM GROWTH October 17, 2017 + Filed by: Impax Laboratories, Inc.
October 17, 2017	425	Impax Laboratories 425 (Prospectus) 425 1 d474533d425.htm 425 Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (“Impax”) and Amneal Pharmaceuticals LLC (“Amneal”)
October 17, 2017	425	Impax Laboratories 425 (Prospectus) 425 Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the Busin
October 17, 2017	425	Impax Laboratories 425 (Prospectus) 425 Filed by: Impax Laboratories, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Impax Laboratories, Inc. Commission File No.: 001-34263 This filing relates to the proposed transaction between Impax Laboratories, Inc. (?Impax?) and Amneal Pharmaceuticals LLC (?Amneal?) pursuant to the Busin
October 17, 2017	425	A STRATEGIC COMBINATION FOR LONG-TERM GROWTH October 17, 2017 + Filed by Amneal Pharmaceuticals LLC pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subj A STRATEGIC COMBINATION FOR LONG-TERM GROWTH October 17, 2017 + Filed by Amneal Pharmaceuticals LLC pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Impax Laboratories, Inc.
October 17, 2017	425	Filed by Amneal Pharmaceuticals LLC 425 Filed by Amneal Pharmaceuticals LLC pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Impax Laboratories, Inc.
October 17, 2017	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 17, 2017 (October 17, 201 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 17, 2017 (October 17, 2017) IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of Incorporation) (Commiss
October 17, 2017	425	CORPORATE OFFICES \| 400 CROSSING BOULEVARD \| BRIDGEWATER, NEW JERSEY 08807 908.947.3120 main \| 908.947.3147 fax \| amneal.com 425 Filed by Amneal Pharmaceuticals LLC pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Impax Laboratories, Inc.
October 17, 2017	EX-99.2	"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This communication includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Ac A STRATEGIC COMBINATION FOR LONG-TERM GROWTH October 17, 2017 + Exhibit 99.2 "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This communication includes ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based on our beliefs and assump
October 17, 2017	EX-99.2	"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This communication includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Ac A STRATEGIC COMBINATION FOR LONG-TERM GROWTH October 17, 2017 + Exhibit 99.2 "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This communication includes ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based on our beliefs and assump
October 17, 2017	EX-2.1	Business Combination Agreement, dated October 17, 2017 by and among Amneal Pharmaceuticals LLC, Impax Laboratories Inc., Atlas Holdings, Inc. and K2 Merger Sub Corporation.* EX-2.1 Exhibit 2.1 EXECUTION VERSION BUSINESS COMBINATION AGREEMENT Dated as of October 17, 2017 By and Among IMPAX LABORATORIES, INC., ATLAS HOLDINGS, INC., K2 MERGER SUB CORPORATION and AMNEAL PHARMACEUTICALS LLC TABLE OF CONTENTS Page ARTICLE I THE TRANSACTIONS 2 Section 1.01 The Holdco Charter Amendment and the Impax Merger; The LLC Conversion; The Contribution and Unit Issuance; The Class B C
October 17, 2017	425	AMNEAL AND IMPAX TO COMBINE Combination Creates Diversified Pharmaceutical Company with 5th Largest Generics Business in the United States Combined Company to Benefit from Expanded Generics Product Portfolio, Premier Diversified Generics Pipeline, Br Filed by Amneal Pharmaceuticals LLC pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Impax Laboratories, Inc.
October 17, 2017	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 17, 2017 (October 17, 201 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 17, 2017 (October 17, 2017) IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State of Incorporation) (Commiss
October 17, 2017	EX-2.1	Business Combination Agreement, dated October 17, 2017 by and among Amneal Pharmaceuticals LLC, Impax Laboratories Inc., Atlas Holdings, Inc. and K2 Merger Sub Corporation.* EX-2.1 Exhibit 2.1 EXECUTION VERSION BUSINESS COMBINATION AGREEMENT Dated as of October 17, 2017 By and Among IMPAX LABORATORIES, INC., ATLAS HOLDINGS, INC., K2 MERGER SUB CORPORATION and AMNEAL PHARMACEUTICALS LLC TABLE OF CONTENTS Page ARTICLE I THE TRANSACTIONS 2 Section 1.01 The Holdco Charter Amendment and the Impax Merger; The LLC Conversion; The Contribution and Unit Issuance; The Class B C
October 17, 2017	EX-99.1	AMNEAL AND IMPAX TO COMBINE Combination Creates Diversified Pharmaceutical Company with 5th Largest Generics Business in the United States Combined Company to Benefit from Expanded Generics Product Portfolio, Premier Diversified Generics Pipeline, Br Exhibit 99.1 FOR IMMEDIATE RELEASE CONTACTS: Amneal Mary Cunney Ogilvy (212) 884-4038 Impax Mark Donohue (215) 558-4526 AMNEAL AND IMPAX TO COMBINE Combination Creates Diversified Pharmaceutical Company with 5th Largest Generics Business in the United States Combined Company to Benefit from Expanded Generics Product Portfolio, Premier Diversified Generics Pipeline, Broad R&D Capabilities Across Do
October 17, 2017	EX-99.1	AMNEAL AND IMPAX TO COMBINE Combination Creates Diversified Pharmaceutical Company with 5th Largest Generics Business in the United States Combined Company to Benefit from Expanded Generics Product Portfolio, Premier Diversified Generics Pipeline, Br Exhibit 99.1 FOR IMMEDIATE RELEASE CONTACTS: Amneal Mary Cunney Ogilvy (212) 884-4038 Impax Mark Donohue (215) 558-4526 AMNEAL AND IMPAX TO COMBINE Combination Creates Diversified Pharmaceutical Company with 5th Largest Generics Business in the United States Combined Company to Benefit from Expanded Generics Product Portfolio, Premier Diversified Generics Pipeline, Broad R&D Capabilities Across Do
August 31, 2017	SC 13G	IPXL / Impax Laboratories, Inc. / Shanghai Fosun Pharmaceutical (Group) Co., Ltd. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Impax Laboratories, Inc. (Name of Issuer) Common Stock, par value US$0.01 per share (Title of Class of Securities) 45256B101 (CUSIP Number) August 21, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the
August 31, 2017	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Exchange Act or any rule or regulation thereunder (including a
August 29, 2017	EX-4.13	IMPAX LABORATORIES, INC. 2001 NON-QUALIFIED EMPLOYEE STOCK PURCHASE PLAN As amended and restated this 16th day of May, 2017 Exhibit Exhibit 4.13 IMPAX LABORATORIES, INC. 2001 NON-QUALIFIED EMPLOYEE STOCK PURCHASE PLAN As amended and restated this 16th day of May, 2017 1. Purpose of Plan. The purpose of the Impax Laboratories, Inc. 2001 Non-Qualified Employee Stock Purchase Plan, as amended and restated from time to time (the ?Plan?), is to enhance employee interest in the success and progress of Impax Laboratories, Inc
August 29, 2017	S-8	Impax Laboratories S-8 S-8 1 ipxl-08x29x2017xformsx8reg.htm S-8 As filed with the Securities and Exchange Commission on August 29, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMPAX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 65-0403311 (State or other jurisdiction
August 9, 2017	EX-99.2	1 Second Quarter 2017 Results and Business Update August 9, 2017 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made i exhibit992to8kq22017 1 Second Quarter 2017 Results and Business Update August 9, 2017 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and express the beliefs and expectations of management.
August 9, 2017	EX-99.1	Impax Reports Solid Second Quarter 2017 Results with Total Revenues Increasing 17% to $202 Million ‒ GAAP Loss Per Share of $0.28; Non-GAAP Adjusted Income Per Share of $0.18 ‒ ‒ Generics Division Revenues Increase 24% to $151 Million ‒ ‒ Significant Exhibit Impax Reports Solid Second Quarter 2017 Results with Total Revenues Increasing 17% to $202 Million ? GAAP Loss Per Share of $0.
August 9, 2017	8-K	Impax Laboratories 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (C
August 9, 2017	EX-10.1	IMPAX LABORATORIES, INC. STOCK OPTION AGREEMENT EX-10.1 2 ipxl-06x30x2017x10qxexx101.htm EXHIBIT 10.1 Exhibit 10.1 IMPAX LABORATORIES, INC. STOCK OPTION AGREEMENT Pursuant to your grant notice (the “Grant Notice”) and this Stock Option Agreement (the “Agreement”), Impax Laboratories, Inc. (the “Company”) has granted you (the “Optionee”) a nontransferable option under the Company’s Fourth Amended and Restated 2002 Equity Incentive Plan, as the s
August 9, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34263 Impax Labor
August 9, 2017	EX-10.2	10. 15.3 Exhibit 10.2 IMPAX LABORATORIES, INC. RESTRICTED STOCK (STOCK BONUS) AWARD AGREEMENT Pursuant to your grant notice (the ?Grant Notice?) and this Restricted Stock (Stock Bonus) Award Agreement (the ?Agreement?), Impax Laboratories, Inc. (the ?Company?) has granted you (the ?Grantee?) a Restricted Stock (Stock Bonus) Award under the Company?s Fourth Amended and Restated 2002 Equity Incentive Plan, a
May 31, 2017	S-8	Impax Laboratories S-8 Document As filed with the Securities and Exchange Commission on May 31, 2017 Registration No.
May 17, 2017	8-K	Impax Laboratories 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (Com
May 10, 2017	EX-99.2	1 First Quarter 2017 Results and Business Update May 10, 2017 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in t exhibit992to8kq12017 1 First Quarter 2017 Results and Business Update May 10, 2017 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and express the beliefs and expectations of management.
May 10, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (Com
May 10, 2017	EX-99.1	Impax Reports First Quarter 2017 Financial Results ⎯ Total Revenues of $184 Million; GAAP Loss Per Share of $1.37; Non-GAAP Adjusted Income Per Share of $0.11 ⎯ ⎯ Announces Plans to Consolidate Manufacturing, Packaging and Generic R&D Operations ⎯ ⎯ Exhibit Impax Reports First Quarter 2017 Financial Results ? Total Revenues of $184 Million; GAAP Loss Per Share of $1.
May 10, 2017	EX-3.2.3	AMENDMENT NO. 6 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.3 AMENDMENT NO. 6 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the ?Bylaws?) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: ?SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
May 10, 2017	EX-3.2.9	BYLAWS OF IMPAX LABORATORIES, INC. (a Delaware corporation) (Amended and Restated as of May 14, 2014) ARTICLE I Exhibit 3.2.9 BYLAWS OF IMPAX LABORATORIES, INC. (a Delaware corporation) (Amended and Restated as of May 14, 2014) ARTICLE I OFFICES SECTION 1. OFFICES. The Corporation shall maintain its registered office in the State of Delaware at 32 Loockerman Square, Suite L-100, in the County of Kent, and its resident agent at such address is the Prentice-Hall Corporation System, Inc. The Corporation may al
May 10, 2017	EX-3.2.7	AMENDMENT NO. 2 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.7 AMENDMENT NO. 2 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
May 10, 2017	EX-3.2.6	AMENDMENT NO. 3 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.6 AMENDMENT NO. 3 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the ?Bylaws?) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: ?SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
May 10, 2017	EX-3.2.2	AMENDMENT NO. 7 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.2 AMENDMENT NO. 7 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
May 10, 2017	EX-3.2.1	AMENDMENT NO. 8 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-3.2.1 2 ipxl-03x31x2017x10qxexx321a.htm EXHIBIT 3.2.1 Exhibit 3.2.1 AMENDMENT NO. 8 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The auth
May 10, 2017	EX-10.2	EMPLOYMENT AGREEMENT EX-10.2 12 ipxl-03x31x2017x10qxexx102.htm EXHIBIT 10.2 Exhibit 10.2 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”), entered into as of March 24, 2017, by and between Impax Laboratories, Inc., a Delaware corporation (the “Company”), and Paul M. Bisaro (the “Executive”). WITNESSETH: WHEREAS, the Executive possesses unique personal knowledge, experience and expertise; WHEREAS, effective as o
May 10, 2017	EX-3.2.4	AMENDMENT NO. 5 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.4 AMENDMENT NO. 5 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the ?Bylaws?) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: ?SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
May 10, 2017	EX-3.2.8	AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC. EX-3.2.8 9 ipxl-03x31x2017x10qxexx328.htm EXHIBIT 3.2.8 Exhibit 3.2.8 AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC. The Amended and Restated Bylaws of Impax Laboratories, Inc. (the “Bylaws”) are hereby amended as follows: 1. Section 5 of Article II shall be amended and restated in its entirety to read as follows: “SECTION 5. QUORUM. At all meetings of stockholders, exc
May 10, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34263 Impax Labo
May 10, 2017	EX-3.2.5	AMENDMENT NO. 4 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-3.2.5 6 ipxl-03x31x2017x10qxexx325.htm EXHIBIT 3.2.5 Exhibit 3.2.5 AMENDMENT NO. 4 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The autho
May 10, 2017	EX-10.3	IMPAX LABORATORIES, INC. STOCK OPTION AGREEMENT EX-10.3 13 ipxl-03x31x2017x10qxexx103.htm EXHIBIT 10.3 Exhibit 10.3 IMPAX LABORATORIES, INC. STOCK OPTION AGREEMENT As an inducement material to the decision by you (the “Optionee”) to accept employment with Impax Laboratories, Inc. (the “Company”) and pursuant to your grant notice (the “Grant Notice”), this Stock Option Agreement (the “Agreement”) and that certain Employment Agreement entered int
May 10, 2017	EX-10.1	AMENDMENT NO. 1 TO CREDIT AGREEMENT EX-10.1 11 ipxl-03x31x2017x10qxexx101.htm EXHIBIT 10.1 Exhibit 10.1 AMENDMENT NO. 1 TO CREDIT AGREEMENT AMENDMENT NO. 1 TO CREDIT AGREEMENT, dated as of March 27, 2017 (this “Agreement”), by and among IMPAX LABORATORIES, INC. (the “Borrower”), Royal Bank of Canada (“Royal Bank”), as administrative agent for the Lenders (in such capacity, the “Administrative Agent”), and each Lender party hereto. P
April 5, 2017	DEFA14A	Impax Laboratories DEFA14A DEFA14A 1 defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitte
April 5, 2017	DEF 14A	Impax Laboratories DEF 14A DEF 14A 1 a2017proxy.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permi
April 5, 2017	8-K	Other Events Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (Co
March 29, 2017	EX-24	EX-24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Mark A.
March 28, 2017	8-K	Impax Laboratories 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (C
March 27, 2017	EX-3.1	AMENDMENT NO. 8 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit AMENDMENT NO. 8 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the ?Bylaws?) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: ?SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor more t
March 27, 2017	8-K	Impax Laboratories 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (C
March 1, 2017	EX-99.2	1 Fourth Quarter and Full Year 2016 Results March 1, 2017 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this exhibit992to8k 1 Fourth Quarter and Full Year 2016 Results March 1, 2017 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and express the beliefs and expectations of management.
March 1, 2017	EX-99.1	Impax Reports Fourth Quarter and Full Year 2016 Financial Results ⎯ Provides 2017 Financial Guidance ⎯ Exhibit Impax Reports Fourth Quarter and Full Year 2016 Financial Results ? Provides 2017 Financial Guidance ? FORT WASHINGTON, PA, March 1, 2017 ? Impax Laboratories, Inc.
March 1, 2017	8-K	Impax Laboratories 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (Co
March 1, 2017	EX-21.1	IMPAX LABORATORIES, INC. Exhibit 21.1 IMPAX LABORATORIES, INC. Subsidiaries of the Registrant as of the date of this report: Name of Subsidiary Jurisdiction of Incorporation or Organization Ownership Amedra Pharmaceuticals LLC Delaware 100% CorePharma, LLC New Jersey 100% Impax Holdings LLC Delaware 100% Impax International Holdings, Inc. Delaware 100% Impax Laboratories Ireland Limited Ireland 100% Impax Laboratories (Ne
March 1, 2017	EX-3.2.5	AMENDMENT NO. 3 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.5 AMENDMENT NO. 3 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the ?Bylaws?) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: ?SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
March 1, 2017	EX-3.2.4	AMENDMENT NO. 4 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-3.2.4 5 ipxl-12x31x2016x10kxexx324.htm EXHIBIT 3.2.4 Exhibit 3.2.4 AMENDMENT NO. 4 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The autho
March 1, 2017	EX-3.2.1	AMENDMENT NO. 7 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.1 AMENDMENT NO. 7 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
March 1, 2017	EX-3.2.7	AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC. Exhibit 3.2.7 AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC. The Amended and Restated Bylaws of Impax Laboratories, Inc. (the ?Bylaws?) are hereby amended as follows: 1. Section 5 of Article II shall be amended and restated in its entirety to read as follows: ?SECTION 5. QUORUM. At all meetings of stockholders, except where otherwise provided by statute, by the Certific
March 1, 2017	EX-3.2.6	AMENDMENT NO. 2 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-3.2.6 7 ipxl-12x31x2016x10kxexx326.htm EXHIBIT 3.2.6 Exhibit 3.2.6 AMENDMENT NO. 2 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The autho
March 1, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34263 Impax Laborato
March 1, 2017	EX-10.19	(Signature Page Follows) Exhibit 10.19 December 19, 2016 J. Kevin Buchi Re: Interim President and Chief Executive Officer Agreement Dear Kevin: On behalf of Impax Laboratories, Inc. (the ?Company?), I am pleased to offer you the position of Interim President and Chief Executive Officer of the Company (?Interim Chief Executive Officer?) on the terms and conditions set forth in this letter agreement (this ?Agreement?). You
March 1, 2017	EX-3.2.2	AMENDMENT NO. 6 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit 3.2.2 AMENDMENT NO. 6 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor
March 1, 2017	EX-10.20.2	General Release and Waiver Exhibit 10.20.2 General Release and Waiver This General Release and Waiver (this ?Release?) is entered into on December 19, 2016 by G. Frederick Wilkinson (the ?Executive?), on the one hand, and Impax Laboratories, Inc. and its subsidiaries and affiliates (collectively, the ?Company?), on the other hand (the Executive and the Company are referred to collectively as the ?Parties?). Defined terms us
March 1, 2017	EX-3.2.3	AMENDMENT NO. 5 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-3.2.3 4 ipxl-12x31x2016x10kxexx323.htm EXHIBIT 3.2.3 Exhibit 3.2.3 AMENDMENT NO. 5 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The autho
March 1, 2017	EX-3.2.8	BYLAWS OF IMPAX LABORATORIES, INC. (a Delaware corporation) (Amended and Restated as of May 14, 2014) ARTICLE I Exhibit 3.2.8 BYLAWS OF IMPAX LABORATORIES, INC. (a Delaware corporation) (Amended and Restated as of May 14, 2014) ARTICLE I OFFICES SECTION 1. OFFICES. The Corporation shall maintain its registered office in the State of Delaware at 32 Loockerman Square, Suite L-100, in the County of Kent, and its resident agent at such address is the Prentice-Hall Corporation System, Inc. The Corporation may al
February 14, 2017	SC 13G/A	IPXL / Impax Laboratories, Inc. / Hound Partners, LLC Passive Investment SC 13G/A 1 d741370513g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) Impax Laboratories, Inc. (Name of Issuer) Class A Common Stock, $.01 Par Value Per Share (Title of Class of Securi
February 13, 2017	SC 13G/A	IPXL / Impax Laboratories, Inc. / ORBIMED ADVISORS LLC - 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 10, 2017	SC 13G/A	IPXL / Impax Laboratories, Inc. / VANGUARD GROUP INC Passive Investment impaxlaboratoriesinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4 )* Name of issuer: Impax Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 45256B101 Date of Event Which Requires Filing of this Statement: December 31, 2016 Check the appropri
February 8, 2017	SC 13G/A	IPXL / Impax Laboratories, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Impax Laboratories Inc (Name of Issuer) Common Stock (Title of Class of Securities) 45256B101 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 7, 2017	LETTER	LETTER Mail Stop 4546 February 07, 2017 VIA E-mail Bryan M. Reasons Senior VP, Finance and Chief Financial Officer Impax Laboratories, Inc. 30831 Huntwood Avenue, Hayward, California 94544 Re: Impax Laboratories, Inc. Form 10-K for Year Ended December 31, 2015 Filed February 22, 2016 File No. 001-34263 Dear Mr. Reasons: We have completed our review of your filing. We remind you that the company and its m
February 2, 2017	CORRESP	Impax Laboratories ESP Document FOIA CONFIDENTIAL TREATMENT REQUESTED BY IMPAX LABORATORIES, INC. PURSUANT TO RULE 83 VIA EDGAR February 2, 2017 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jim B. Rosenberg Senior Assistant Chief Accountant Office of Healthcare and Insurance Re: Impax Laboratories, Inc. Form 10-K for the Fiscal Year Ended
January 19, 2017	LETTER	LETTER Mail Stop 4546 January 19, 2017 VIA E-mail Bryan M. Reasons Senior VP, Finance and Chief Financial Officer Impax Laboratories, Inc. 30831 Huntwood Avenue, Hayward, California 94544 Re: Impax Laboratories, Inc. Form 10-K for Year Ended December 31, 2015 Filed February 22, 2016 File No. 001-34263 Dear Mr. Reasons: We have reviewed your December 27, 2016 response to our comment letter and have the fo
January 13, 2017	CT ORDER	Impax Laboratories RDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION January 17, 2017 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Impax Laboratories, Inc.
January 12, 2017	SC 13G/A	Impax Laboratories 3G/A (Passive Acquisition of More Than 5% of Shares) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) IMPAX LABORATORIES INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 45256B101 - (CUSIP Number) December 31, 2016 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
January 11, 2017	8-K	Impax Laboratories 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2017 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation)
January 11, 2017	EX-99.1	1 35th Annual J.P. Morgan Healthcare Conference January 11, 2017 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made i exhibit991to8k 1 35th Annual J.P. Morgan Healthcare Conference January 11, 2017 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this news release contain information that is not historical; these statements are forward-looking in nature and express the beliefs
January 6, 2017	EX-10.5.1	SUPPLY AGREEMENT ACTAVIS ELIZABETH LLC ACTAVIS GROUP PTC EHF ACTAVIS HOLDCO US, INC. ACTAVIS LLC ACTAVIS MID ATLANTIC LLC ACTAVIS PHARMA, INC. ACTAVIS SOUTH ATLANTIC LLC ANDRX LLC BREATH LTD. THE RUGBY GROUP, INC. WATSON LABORATORIES, INC. IMPAX LABO EXECUTION VERSION SUPPLY AGREEMENT AMONG ACTAVIS ELIZABETH LLC ACTAVIS GROUP PTC EHF ACTAVIS HOLDCO US, INC.
January 6, 2017	EX-10.5.2	AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT THIS AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT (this ?Amendment?) is dated as of June 30, 2016, by and among Impax Laboratories, Inc., a Delaware corporation (?Buyer?), Actavis Elizabeth LLC, a Delaware limited liability company (?Actavis Elizabeth?), Actavis Group PTC Ehf., an Iceland einkahlutafelag (?Actavis PTC?), Actavis Holdco US, Inc., a Delaware corpor
January 6, 2017	EX-10.4.2	AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT EXECUTION VERSION AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT THIS AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT (this ?Amendment?) is dated as of June 30, 2016, by and between Impax Laboratories, Inc., a Delaware corporation (?Buyer?) and Teva Pharmaceutical Industries Ltd., an Israeli corporation, acting directly or through its Affiliates (?Manufacturer?). WITNESSETH: WHEREAS, Buyer and the Manufacturer e
January 6, 2017	EX-10.2.1	ASSET PURCHASE AGREEMENT TEVA PHARMACEUTICAL INDUSTRIES LTD. IMPAX LABORATORIES, INC. DATED AS OF JUNE 20, 2016 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 6 SECTION 1.1. Definitions 6 SECTION 1.2. Interpretation 12 SECTION 1.3. Currency 12 SECTION EX-10.2.1 2 ipxl-06x30x2016x10qaxexx1021.htm EXHIBIT 10.2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT BETWEEN TEVA PHARMACEUTICAL INDUSTRIES LTD. AND IMPAX LABORATORIES, INC. DATED AS OF JUNE 20, 2016 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 6 SECTION 1.1. Definitions 6 SECTION 1.2. Interpretation 12 SECTION 1.3. Currency 12 SECTION 1.4. Incorporation by Reference and Supremacy of FTC Order
January 6, 2017	EX-10.3.1	ASSET PURCHASE AGREEMENT ACTAVIS ELIZABETH LLC ACTAVIS GROUP PTC EHF ACTAVIS HOLDCO US, INC. ACTAVIS LLC ACTAVIS MID ATLANTIC LLC ACTAVIS PHARMA, INC. ACTAVIS SOUTH ATLANTIC LLC ANDRX LLC BREATH LTD. THE RUGBY GROUP, INC. WATSON LABORATORIES, INC. IM EX-10.3.1 3 ipxl-06x30x2016x10qaxexx1031.htm EXHIBIT 10.3.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT AMONG ACTAVIS ELIZABETH LLC ACTAVIS GROUP PTC EHF ACTAVIS HOLDCO US, INC. ACTAVIS LLC ACTAVIS MID ATLANTIC LLC ACTAVIS PHARMA, INC. ACTAVIS SOUTH ATLANTIC LLC ANDRX LLC BREATH LTD. THE RUGBY GROUP, INC. WATSON LABORATORIES, INC. AND IMPAX LABORATORIES, INC. DATED AS OF JUNE 20, 2016 TABLE OF CONT
January 6, 2017	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34263 Impax Lab
January 6, 2017	EX-10.4.1	SUPPLY AGREEMENT TEVA PHARMACEUTICAL INDUSTRIES LTD. IMPAX LABORATORIES, INC. DATED AS OF JUNE 20, 2016 TABLE OF CONTENTS Page Article I. DEFINITIONS 3 Section 1.1. Definitions. 3 Section 1.2. Incorporation by Reference and Supremacy of FTC Order 5 A EXECUTION VERSION SUPPLY AGREEMENT BETWEEN TEVA PHARMACEUTICAL INDUSTRIES LTD. AND IMPAX LABORATORIES, INC. DATED AS OF JUNE 20, 2016 TABLE OF CONTENTS Page Article I. DEFINITIONS 3 Section 1.1. Definitions. 3 Section 1.2. Incorporation by Reference and Supremacy of FTC Order 5 Article II. MANUFACTURE AND SALE OF SUPPLY PRODUCTS 5 Section 2.1. Engagement. 5 Section 2.2. Sale and Distribution. 6 Se
December 27, 2016	CORRESP	Impax Laboratories ESP Document FOIA CONFIDENTIAL TREATMENT REQUESTED BY IMPAX LABORATORIES, INC. PURSUANT TO RULE 83 VIA EDGAR December 27, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jim B. Rosenberg Senior Assistant Chief Accountant Office of Healthcare and Insurance Re: Impax Laboratories, Inc. Form 10-K for the Fiscal Year Ended
December 20, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits 8-K 1 ipxl-12x20x2016x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2016 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisd
December 20, 2016	EX-3.1	AMENDMENT NO. 7 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit AMENDMENT NO. 7 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the ?Bylaws?) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: ?SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor more t
December 13, 2016	LETTER	LETTER Mail Stop 4546 December 12, 2016 VIA E-mail Bryan M. Reasons Senior VP, Finance and Chief Financial Officer Impax Laboratories, Inc. 30831 Huntwood Avenue, Hayward, California 94544 Re: Impax Laboratories, Inc. Form 10-K for Year Ended December 31, 2015 Filed February 22, 2016 File No. 001-34263 Dear Mr. Reasons: We have reviewed your December 1, 2016 response to our comment letter and have the fo
December 1, 2016	CORRESP	Impax Laboratories ESP Document VIA EDGAR December 1, 2016 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 28, 2016	8-K	Impax Laboratories 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2016 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation)
November 28, 2016	EX-3.1	AMENDMENT NO. 6 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-3.1 2 ipxl-11x28x2016x8kxex31.htm EXHIBIT 3.1 AMENDMENT NO. 6 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of direc
November 28, 2016	EX-24	EX-24 POWER OF ATTORNEY Know all by these present, that the undersigned hereby constitutes and appoints each of Mark A.
November 17, 2016	LETTER	LETTER Mail Stop 4546 November 17, 2016 VIA E-mail Bryan Reasons Senior VP, Finance and Chief Financial Officer Impax Laboratories, Inc.
November 9, 2016	EX-99.2	1 Third Quarter 2016 Financial Results and Business Update November 9, 2016 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statem ipxl110920168kex992 1 Third Quarter 2016 Financial Results and Business Update November 9, 2016 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and express the beliefs and expectations of management.
November 9, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2016 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation)
November 9, 2016	EX-99.1	Impax Reports Third Quarter 2016 Financial Results —Third Quarter 2016 Revenue of $228 Million — — GAAP Loss Per Share of $2.51 Includes Non-Cash Impairment Charges— — Adjusted Diluted EPS of $0.37 — — Company Updates Full Year 2016 Financial Guidanc Exhibit Impax Reports Third Quarter 2016 Financial Results ?Third Quarter 2016 Revenue of $228 Million ? ? GAAP Loss Per Share of $2.
November 9, 2016	EX-3.2.4	AMENDMENT NO. 3 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED AMENDMENT NO. 3 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the ?Bylaws?) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: ?SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor more than nine
November 9, 2016	EX-3.2.3	AMENDMENT NO. 2 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-3.2.3 4 ipxl-09x30x2016x10qxexx323.htm EXHIBIT 3.2.3 AMENDMENT NO. 2 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number o
November 9, 2016	EX-3.2.6	AMENDMENT NO. 5 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-3.2.6 7 ipxl-09x30x2016x10qxexx326.htm EXHIBIT 3.2.6 AMENDMENT NO. 5 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number o
November 9, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34263 Impax
November 9, 2016	EX-3.2.1	BYLAWS OF IMPAX LABORATORIES, INC. (a Delaware corporation) (Amended and Restated as of May 14, 2014) ARTICLE I BYLAWS OF IMPAX LABORATORIES, INC. (a Delaware corporation) (Amended and Restated as of May 14, 2014) ARTICLE I OFFICES SECTION 1. OFFICES. The Corporation shall maintain its registered office in the State of Delaware at 32 Loockerman Square, Suite L-100, in the County of Kent, and its resident agent at such address is the Prentice-Hall Corporation System, Inc. The Corporation may also have and ma
November 9, 2016	EX-3.2.5	AMENDMENT NO. 4 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED AMENDMENT NO. 4 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor more than seve
November 9, 2016	EX-3.2.2	AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC. AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC. The Amended and Restated Bylaws of Impax Laboratories, Inc. (the “Bylaws”) are hereby amended as follows: 1. Section 5 of Article II shall be amended and restated in its entirety to read as follows: “SECTION 5. QUORUM. At all meetings of stockholders, except where otherwise provided by statute, by the Certificate, or by the
October 19, 2016	EX-99.3	Certain Pharmaceutical Products of Teva Pharmaceutical Industries Limited Exhibit Exhibit 99.3 Certain Pharmaceutical Products of Teva Pharmaceutical Industries Limited Unaudited Special Purpose Combined Financial Statements of Assets Acquired as of June 30, 2016 and December 31, 2015, and Unaudited Special Purpose Combined Statements of Revenue and Direct Expenses of the Six Months Ended June 30, 2016 and 2015. Certain Pharmaceutical Products of Teva Pharmaceutical Ind
October 19, 2016	EX-99.4	Certain Pharmaceutical Products of Allergan plc Unaudited Special Purpose Combined Statements of Net Assets Acquired as of June 30, 2016 and December 31, 2015 and Special Purpose Combined Statements of Revenues and Direct Expenses for the six months Exhibit Exhibit 99.4 Certain Pharmaceutical Products of Allergan plc Unaudited Special Purpose Combined Statements of Net Assets Acquired as of June 30, 2016 and December 31, 2015 and Special Purpose Combined Statements of Revenues and Direct Expenses for the six months ended June 30, 2016 and June 30, 2015 Certain Pharmaceutical Products of Allergan plc Index to Unaudited Special Purpose Combined
October 19, 2016	8-K/A	Impax Laboratories 8-K/A (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2016 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction
October 19, 2016	EX-99.1	Certain Pharmaceutical Products of Teva Pharmaceutical Industries Limited Exhibit Exhibit 99.1 Certain Pharmaceutical Products of Teva Pharmaceutical Industries Limited Special Purpose Combined Financial Statements of Assets Acquired as of December 31, 2015 and 2014, and Special Purpose Combined Statements of Revenue and Direct Expenses of the Years Ended December 31, 2015, 2014 and 2013. Certain Pharmaceutical Products of Teva Pharmaceutical Industries Limited INDEX In
October 19, 2016	EX-99.2	Certain Pharmaceutical Products of Allergan plc Special Purpose Combined Statements of Net Assets Acquired as of December 31, 2015 and December 31, 2014 and Special Purpose Combined Statements of Revenues and Direct Expenses for the years ended Decem Exhibit Exhibit 99.2 Certain Pharmaceutical Products of Allergan plc Special Purpose Combined Statements of Net Assets Acquired as of December 31, 2015 and December 31, 2014 and Special Purpose Combined Statements of Revenues and Direct Expenses for the years ended December 31, 2015, 2014 and 2013 Certain Pharmaceutical Products of Allergan plc Index to Unaudited Special Purpose Combined Financial
October 19, 2016	EX-99.5	IMPAX LABORATORIES, INC. UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Exhibit Exhibit 99.5 IMPAX LABORATORIES, INC. UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION This unaudited pro forma combined financial information of Impax Laboratories, Inc. ("Impax" or the "Company") is presented to illustrate the estimated effects of the Teva Transaction and the $400.0 million of borrowing under the Term Loan Facility used to finance the Teva Transaction. See "Note 1. Des
September 16, 2016	EX-4.4	AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC. Exhibit AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC. The Amended and Restated Bylaws of Impax Laboratories, Inc. (the ?Bylaws?) are hereby amended as follows: 1. Section 5 of Article II shall be amended and restated in its entirety to read as follows: ?SECTION 5. QUORUM. At all meetings of stockholders, except where otherwise provided by statute, by the Certificate, o
September 16, 2016	EX-4.7	AMENDMENT NO. 4 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-4.7 6 ipxl-09152016s8ex47.htm EXHIBIT 4.7 AMENDMENT NO. 4 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors
September 16, 2016	EX-4.3	BYLAWS OF IMPAX LABORATORIES, INC. (a Delaware corporation) (Amended and Restated as of May 14, 2014) ARTICLE I Exhibit BYLAWS OF IMPAX LABORATORIES, INC. (a Delaware corporation) (Amended and Restated as of May 14, 2014) ARTICLE I OFFICES SECTION 1. OFFICES. The Corporation shall maintain its registered office in the State of Delaware at 32 Loockerman Square, Suite L-100, in the County of Kent, and its resident agent at such address is the Prentice-Hall Corporation System, Inc. The Corporation may also hav
September 16, 2016	EX-4.8	AMENDMENT NO. 5 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit AMENDMENT NO. 5 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the ?Bylaws?) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: ?SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor more t
September 16, 2016	S-8	Impax Laboratories S-8 Document As filed with the Securities and Exchange Commission on September 16, 2016 Registration No.
September 16, 2016	EX-4.5	AMENDMENT NO. 2 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED Exhibit AMENDMENT NO. 2 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the ?Bylaws?) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: ?SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor more t
September 16, 2016	EX-4.6	AMENDMENT NO. 3 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED EX-4.6 5 ipxl-09152016s8ex46.htm EXHIBIT 4.6 AMENDMENT NO. 3 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors
August 22, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2016 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (
August 22, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2016 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (
August 22, 2016	EX-3.1	AMENDMENT NO. 5 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED AMENDMENT NO. 5 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the ?Bylaws?) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: ?SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor more than eigh
August 9, 2016	EX-99.2	1 Second Quarter 2016 Earnings Conference Call August 9, 2016 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in t exhibit992 1 Second Quarter 2016 Earnings Conference Call August 9, 2016 2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and express the beliefs and expectations of management.
August 9, 2016	EX-99.1	Impax Reports Second Quarter 2016 Financial Results — Second Quarter 2016 Revenue of $173 Million — — GAAP Loss Per Share of $0.04 and Adjusted Diluted EPS of $0.21— — Company Updates Full Year 2016 Financial Guidance — — Company Announces Positive R Exhibit Impax Reports Second Quarter 2016 Financial Results ? Second Quarter 2016 Revenue of $173 Million ? ? GAAP Loss Per Share of $0.
August 9, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2016 Impax Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34263 65-0403311 (State or other jurisdiction of incorporation) (C
August 9, 2016	EX-3.1.1	AMENDMENT NO. 4 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED AMENDMENT NO. 4 TO AMENDED AND RESTATED BYLAWS OF IMPAX LABORATORIES, INC., AS AMENDED The Amended and Restated Bylaws of Impax Laboratories, Inc., as amended (the “Bylaws”) are hereby amended as follows: 1. Section 14 of Article III shall be amended and restated in its entirety to read as follows: “SECTION 14. NUMBER. The authorized number of directors shall be no less than one nor more than seve
August 9, 2016	EX-10.2.1	ASSET PURCHASE AGREEMENT TEVA PHARMACEUTICAL INDUSTRIES LTD. IMPAX LABORATORIES, INC. DATED AS OF JUNE 20, 2016 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 6 SECTION 1.1. Definitions 6 SECTION 1.2. Interpretation 12 SECTION 1.3. Currency 12 SECTION EXECUTION VERSION ASSET PURCHASE AGREEMENT BETWEEN TEVA PHARMACEUTICAL INDUSTRIES LTD.
August 9, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34263 Impax Labor
August 9, 2016	EX-10.1	FIRST AMENDMENT TO DISTRIBUTION, LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT FIRST AMENDMENT TO DISTRIBUTION, LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT This First Amendment to Distribution, License, Development and Supply Agreement (the “Amendment”) is made and entered into effective as of May 31, 2016 (the “Effective Date”) by and between AstraZeneca UK Limited, a company incorporated in England under no.
August 9, 2016	EX-10.3.1	ASSET PURCHASE AGREEMENT ACTAVIS ELIZABETH LLC ACTAVIS GROUP PTC EHF ACTAVIS HOLDCO US, INC. ACTAVIS LLC ACTAVIS MID ATLANTIC LLC ACTAVIS PHARMA, INC. ACTAVIS SOUTH ATLANTIC LLC ANDRX LLC BREATH LTD. THE RUGBY GROUP, INC. WATSON LABORATORIES, INC. IM EXECUTION VERSION ASSET PURCHASE AGREEMENT AMONG ACTAVIS ELIZABETH LLC ACTAVIS GROUP PTC EHF ACTAVIS HOLDCO US, INC.

IPXL / Impax Laboratories, Inc. - SEC 보고서, 연례 보고, 기업 사업 설명서

기본 통계

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?